Affordable GLP-1 providers: the under-$300 field, annualized honestly
Updated 2026-08-10 · figures captured 2026-08-09 · how we verify
Affordability is an annual property, not a first-month property, so this page draws the line at $300/month at maintenance and shows the year. Tirzepatide programs that clear the bar: NexLife↗ at $215 ($2,580/yr); Yucca Health↗ at $258 ($3,096/yr); IVIM Health↗ at $278 ($3,336/yr); Mochi Health↗ at $278 ($3,336/yr); ShedRx↗ at $289 ($3,468/yr); Found at $289 ($3,468/yr); SkinnyRx↗ at $299 ($3,588/yr); OrderlyMeds↗ at $299 ($3,588/yr). On the semaglutide side, effectively the whole verified index qualifies, from Oak Longevity at $133 ($1,596/yr) upward — the full table has all of it.
Two affordability traps this page's basis is built to catch: programs that are affordable only at the starter dose (the reason Fifty 410↗'s $133 is absent), and programs affordable only before the mandatory membership joins (the reason Mochi appears at $278, not $199). Brand context: Zepbound's $449 maintenance price now sits within $149 of this page's cutoff — affordability increasingly includes the approved product.
RANK01
NexLife
Dose-flat — the maintenance price equals the starter price; no membership fee; shipping included.
$215/MO ALL-IN
RANK02
Yucca Health
Dose-flat — the maintenance price equals the starter price; no membership fee; shipping included.
$258/MO ALL-IN
RANK04
Mochi Health
Dose-flat — the maintenance price equals the starter price; $79/mo membership already inside the figure; shipping included.
$278/MO ALL-IN
RANK06
Found
Dose-flat — the maintenance price equals the starter price; no membership fee; shipping included.
THIRD-PARTY REPORTED · captured 2026-08-05 · source · archive
$289/MO ALL-IN
RANK07
SkinnyRx
Dose-flat — the maintenance price equals the starter price; no membership fee; shipping included.
$299/MO ALL-IN
RANK08
OrderlyMeds
Dose-flat — the maintenance price equals the starter price; no membership fee; shipping included.
$299/MO ALL-IN
Prepaid rates are excluded from the monthly cutoff (they are commitments, compared separately in the annual analysis); microdose and ODT tiers are separate products and never blend into these figures.
The leaders, across a full year
Monthly figures flatter everyone equally; a year separates them. The field, annualized on the same all-in basis: NexLife: $2,580 monthly-billed, $2,232 on its prepaid path (upfront); Yucca Health: $3,096 monthly-billed; IVIM Health: $3,336 monthly-billed; Mochi Health: $3,336 monthly-billed; ShedRx: $3,468 monthly-billed; Found: $3,468 monthly-billed; SkinnyRx: $3,588 monthly-billed; OrderlyMeds: $3,588 monthly-billed.
Spread top-to-bottom within just these five: $1,008 a year — before considering the rest of the field, where the verified ceiling reaches $3,588. Prepaid paths shrink the totals and add commitment; the trade is priced properly in the annual-cost analysis and at your own numbers in the calculator.
Structure census across the 8 priced programs above: 6 are dose-flat, 6 carry no membership, 2 name their pharmacy network, and 1 publish a prepaid path below their own monthly-billed year. Those four counts are the shape of this list — the price column tells you what a program charges; the census tells you what kind of thing it is.
How to use a list like this well: shortlist two or three, pull each provider page, and read the record — structure, exit terms, pharmacy transparency, evidence flags — before letting the price column decide. The ranking gets you to the right neighborhood; the records keep you out of the wrong house.
Frequently asked
What is the cheapest option on this list?
NexLife at $215 per month all-in on the maintenance basis, captured 2026-08-10. Every figure here is medication plus mandatory fees; confirm at the provider's checkout before enrolling.
How is this ranking produced?
By sorting the public dataset on verified all-in monthly price at the maintenance dose — no editorial reordering, no paid placement. Basis, exclusions, and verification cycle: /methodology/; recompute it yourself from the JSON.
Are compounded GLP-1s on this page FDA-approved?
No compounded product is FDA-approved. Since 2025 compounded tirzepatide and semaglutide are limited to patient-specific 503A prescriptions with documented clinical need; brand options (Zepbound, Wegovy) are the approved products. Regulatory timeline: here.